Electronic cigarettes pose less danger than traditional smoking

Jul.08.2022
Electronic cigarettes pose less danger than traditional smoking
Evidence shows that vaping is less harmful than smoking and can help smokers quit, but media coverage has hindered public understanding.

The evidence is clear: vaping is less dangerous than smoking and can help many people quit their deadly smoking habit. No public data can refute these two conclusions, but tobacco control researchers, activists, and federal regulatory agencies often deny or downplay these observations. This contaminates the public's understanding of electronic cigarettes and prevents smokers from trying out alternative solutions that could potentially save their lives.


Using electronic cigarettes helped me successfully quit smoking, according to a recent conclusion published in the American Journal of Preventive Medicine. Medscape reported on June 20 that "an increasing number of American adults believe that electronic cigarettes are more harmful than traditional cigarettes.


Why are the public afraid of electronic cigarettes?


The author analyzed data collected as part of the Health Information National Trends Survey (HINTS), which is a nationally representative survey conducted through mail that asks American adults about their attitudes towards cancer and other health-related information. The data was collected over five cycles between January 2018 and May 2020, with over 3000 respondents included in the final analysis each year (3360 in 2018, 3217 in 2019, and 3677 in 2020). The author reports that...


The relative perceived harm of electronic cigarettes versus traditional cigarettes was assessed through the following question with six possible answers: Compared to smoking, would you say that electronic cigarettes are... Respondents were categorized as perceiving electronic cigarettes to be less harmful (less harmful or much less harmful) than traditional cigarettes, equally harmful, or more harmful (more harmful or much more harmful) than traditional cigarettes.


The author suggests that the negative shift in perception may have been driven by the media's coverage of the so-called "EVALI outbreak". From 2019 to 2020, over 2,000 individuals were hospitalized due to e-cigarette related lung injuries and 68 people died.


These cases were not caused by electronic cigarettes themselves, which were mistakenly maintained by the Centers for Disease Control and Prevention for a few months, but by devices purchased illegally for vaping THC or CBD. These chemicals, derived from cannabis rather than tobacco, were mixed with vitamin E acetate which may have contributed to the reported lung injuries. Dr. Josh Bloom provided a helpful explanation of the chemical reaction behind this phenomenon in the story, which subsequent research has confirmed.


During the outbreak of EVALI, journalists did what they often do without having all the facts: they amplified the risk, with the tacit approval of the Centers for Disease Control, but were not interested in reporting on the controversy surrounding the decision. According to the study authors:


In March and April of 2020, there was a high level of harmful relative opinions. This suggests that misunderstandings have persisted since the initial discovery of the connection to vitamin E acetate in September 2019, possibly due to media coverage not remaining at the same level after the source of the epidemic was determined.


The trend is still continuing.


EVALI is no longer a major public health concern, but controversial ideological radicalism and careless reporting continue to undermine electronic cigarettes as a harm reduction tool in today's society. Researchers have published low-quality studies alleging serious health consequences from using e-cigarettes, and the media dutifully reported on these findings. The ACSH and other scientifically-minded media outlets have corrected the propaganda, but unfortunately, this good news has not garnered as much attention as sensational and scary headlines.


Experts recognize the issue and acknowledge the need for a solution. According to a doctor, we are effective at communicating the harmful effects of smoking and the dangers of tobacco in public health. Ashley Brooks-Russell, associate professor at the Colorado School of Public Health, stated to Medscape Medical News that we struggle to discuss smaller choices, such as the lesser harm of e-cigarettes compared to smoking.


Dr. Russell is correct, but I will go even further. Even though researchers have documented the harm caused by common anti-vaping metaphors, tobacco researchers cannot abandon their skepticism of e-cigarettes. As the authors of the study themselves have written,


Electronic cigarettes contain high levels of nicotine and appealing flavors that may lead to addiction and the use of combustible tobacco products among adolescents and young adults.


The sentence is at least partially false. Many electronic cigarettes contain little to no nicotine. Flavored electronic cigarettes do not encourage youth to use any tobacco products, and there is no concrete evidence to support this speculation. The author also reiterated the anti-electronic cigarette stance, which has become a staunch article among tobacco researchers: "The risks associated with long-term use are still unclear." This is undoubtedly true, as no one has a crystal ball, but public health researchers often use such language to suggest that we will discover some serious risks associated with electronic cigarettes in the future.


The American Cancer Society claims that the long-term risks of only using electronic cigarettes are not yet fully clear. However, there is increasing evidence that using e-cigarettes has negative effects on the cardiovascular system and lungs. If immediate action is not taken to stop the widespread use of these products, the long-term adverse health effects will increase.


Can you imagine a large medical institution issuing a statement similar to this regarding the use of COVID-19 vaccines or puberty blockers for treating gender dysphoria? After all, we do not know the potential long-term effects of these powerful drugs on those who take them. Of course, until we have a better understanding of these products, we must halt their "popular use," shouldn't we?


If these issues are frustrating you, then maybe you're starting to understand why the popular rhetoric surrounding e-cigarettes is so absurd. Properly evaluating any product requires accurately balancing its risks and benefits. No one is claiming that e-cigarettes are risk-free; they are an effective intervention aimed at reducing the harm of smoking, which is killing people all over the world.


Given this standard, speculating about potential hazards we may discover one day is a foolish thought exercise. Let the public know what we know today: for adult smokers who want to quit smoking, electronic cigarettes are a low-risk option.


This article is compiled from third-party information and is only intended for educational purposes. The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
Bret Koplow, acting director of the U.S. Food and Drug Administration's Center for Tobacco Products, will deliver a keynote and participate in a fireside chat at the National Association of Tobacco Outlets' Sept. 29-30 conference in Washington. His appearance comes months after the FDA moved to accelerate PMTA reviews and introduced a more differentiated enforcement policy for certain unauthorized ENDS and oral nicotine pouch products. The agency also plans a public list identifying manufacturers and products it does not currently intend to prioritize for enforcement under the May guidance. NATO says its membership includes more than 66,000 retail stores, making product-status transparency and enforcement boundaries directly relevant to the retail sector.
Aug.14
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan Industrial Co., Ltd. has filed a patent application for a cellulose-free scaffold material for nicotine pouches, proposing a combination of bioceramic material, polydextrose and sugar alcohols to replace conventional microcrystalline cellulose and cellulose derivatives. The filing aims to address issues including powdery mouthfeel, residue and limited release control, while also reducing reliance on existing cellulose-based patent portfolios. In patent examples, one fast-release formulation reached a nicotine release rate of 50% at 10 minutes and more than 90% at 20 minutes.
Sep.02
UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
The UK’s Vaping Products Duty (VPD), scheduled to take effect in October 2026, is prompting retailers to assess how different vape categories may be affected. UK retailer Vape HQ has estimated potential price changes under the new volume-based tax system, showing that 100ml shortfill e-liquids could see prices rise from around £12.99 to £39.39, a 203% increase, while 2ml prefilled pod vape kits could rise from £5.99 to £6.52, an increase of about 9%. The estimates highlight how a volume-based tax structure creates uneven cost impacts across product categories.
Aug.19
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
AIR’s first half-year results as a listed company offer a new test of how far a traditional hookah business can transform. H1 2026 revenue rose 3.7%, even as Flavored Shisha Molasses shipments fell 9%, with pricing and mix supporting growth. Traditional shisha still generates almost all revenue, while OOKA, Crown Switch, Greentank and U.S. regulatory spending point to accelerating diversification. The next test is whether those investments can become a second business of meaningful scale and profitability.
Capital Markets
Aug.21